Diastolic dysfunction and thin filament dysregulation resulting from excitation-contraction uncoupling in a mouse model of restrictive cardiomyopathy

Journal of Molecular and Cellular Cardiology

Volumn 53, Issue 3, 2012, Pages 446-457

  Davis, Jennifer ^a,b   Yasuda, Soichiro ^a   Palpant, Nathan J ^a,c   Martindale, Joshua ^a   Stevenson, Tamara ^a,d   Converso, Kimber ^a,d   Metzger, Joseph M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cardiac troponin I; Hypertrophic cardiomyopathy; Restrictive cardiomyopathy

Indexed keywords

CALCIUM ION; PHOSPHOLAMBAN; TROPONIN I;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CURRENT; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; EXCITATION CONTRACTION COUPLING; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE ENDDIASTOLIC PRESSURE; IN VIVO STUDY; MISSENSE MUTATION; MOUSE; MYOFILAMENT; NONHUMAN; PRIORITY JOURNAL; RESTRICTIVE CARDIOMYOPATHY; SARCOMERE; THIN FILAMENT; TRANSGENIC MOUSE;

ANIMALS; CALCIUM; CARDIOMYOPATHY, RESTRICTIVE; DISEASE MODELS, ANIMAL; EXCITATION CONTRACTION COUPLING; MICE; MICE, TRANSGENIC; MUTATION; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; SARCOMERES; TROPONIN I;

MUS MUSCULUS;

EID: 84864796741     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.05.018     Document Type: Article

References (46)

1. Kushwaha S.S., Fallon J.T., Fuster V. Restrictive cardiomyopathy. N Engl J Med 1997, 336:267-276.
2. Maron B.J., Towbin J.A., Thiene G., Antzelevitch C., Corrado D., Arnett D., et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006, 113:1807-1816.
3. Mogensen J., Kubo T., Duque M., Uribe W., Shaw A., Murphy R., et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest 2003, 111:209-216.
4. Metzger J.M., Westfall M.V. Covalent and noncovalent modification of thin filament action: the essential role of troponin in cardiac muscle regulation. Circ Res 2004, 94:146-158.
5. Mogensen J., Murphy R.T., Kubo T., Bahl A., Moon J.C., Klausen I.C., et al. Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004, 44:2315-2325.
6. Braunwald E., Seidman C.E., Sigwart U. Contemporary evaluation and management of hypertrophic cardiomyopathy. Circulation 2002, 106:1312-1316.
7. Fatkin D., Graham R.M. Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 2002, 82:945-980.
8. Geisterfer-Lowrance A.A., Kass S., Tanigawa G., Vosberg H.P., McKenna W., Seidman C.E., et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 1990, 62:999-1006.
9. Maron B.J., Shirani J., Poliac L.C., Mathenge R., Roberts W.C., Mueller F.O. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996, 276:199-204.
10. Blumenschein T.M., Stone D.B., Fletterick R.J., Mendelson R.A., Sykes B.D. Dynamics of the C-terminal region of TnI in the troponin complex in solution. Biophys J 2006, 90:2436-2444.
11. Gomes A.V., Potter J.D. Cellular and molecular aspects of familial hypertrophic cardiomyopathy caused by mutations in the cardiac troponin I gene. Mol Cell Biochem 2004, 263:99-114.
12. Pirani A., Vinogradova M.V., Curmi P.M., King W.A., Fletterick R.J., Craig R., et al. An atomic model of the thin filament in the relaxed and Ca2+-activated states. J Mol Biol 2006, 357:707-717.
13. Solaro R.J., Van Eyk J. Altered interactions among thin filament proteins modulate cardiac function. J Mol Cell Cardiol 1996, 28:217-230.
14. Davis J., Wen H., Edwards T., Metzger J.M. Thin filament disinhibition by restrictive cardiomyopathy mutant R193H troponin I induces Ca2+-independent mechanical tone and acute myocyte remodeling. Circ Res 2007, 100:1494-1502.
15. Kobayashi T., Solaro R.J. Increased Ca2+ affinity of cardiac thin filaments reconstituted with cardiomyopathy-related mutant cardiac troponin I. J Biol Chem 2006, 281:13471-13477.
16. Gomes A.V., Liang J., Potter J.D. Mutations in human cardiac troponin I that are associated with restrictive cardiomyopathy affect basal ATPase activity and the calcium sensitivity of force development. J Biol Chem 2005, 280:30909-30915.
17. Yumoto F., Lu Q.W., Morimoto S., Tanaka H., Kono N., Nagata K., et al. Drastic Ca2+ sensitization of myofilament associated with a small structural change in troponin I in inherited restrictive cardiomyopathy. Biochem Biophys Res Commun 2005, 338:1519-1526.
18. Li Y., Charles P.Y., Nan C., Pinto J.R., Wang Y., Liang J., et al. Correcting diastolic dysfunction by Ca2+ desensitizing troponin in a transgenic mouse model of restrictive cardiomyopathy. J Mol Cell Cardiol 2010, 49:402-411.
19. Du J., Liu J., Feng H.Z., Hossain M.M., Gobara N., Zhang C., et al. Impaired relaxation is the main manifestation in transgenic mice expressing a restrictive cardiomyopathy mutation, R193H, in cardiac TnI. Am J Physiol Heart Circ Physiol 2008, 294:H2604-H2613.
20. Du J., Zhang C., Liu J., Sidky C., Huang X.P. A point mutation (R192H) in the C-terminus of human cardiac troponin I causes diastolic dysfunction in transgenic mice. Arch Biochem Biophys 2006, 456:143-150.
21. Davis J., Wen H., Edwards T., Metzger J.M. Allele and species dependent contractile defects by restrictive and hypertrophic cardiomyopathy-linked troponin I mutants. J Mol Cell Cardiol 2008, 44:891-904.
22. Day S.M., Westfall M.V., Fomicheva E.V., Hoyer K., Yasuda S., La Cross N.C., et al. Histidine button engineered into cardiac troponin I protects the ischemic and failing heart. Nat Med 2006, 12:181-189.
23. James J., Zhang Y., Osinska H., Sanbe A., Klevitsky R., Hewett T.E., et al. Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy. Circ Res 2000, 87:805-811.
24. Sanbe A., James J., Tuzcu V., Nas S., Martin L., Gulick J., et al. Transgenic rabbit model for human troponin I-based hypertrophic cardiomyopathy. Circulation 2005, 111:2330-2338.
25. Yasuda S., Coutu P., Sadayappan S., Robbins J., Metzger J.M. Cardiac transgenic and gene transfer strategies converge to support an important role for troponin I in regulating relaxation in cardiac myocytes. Circ Res 2007, 101:377-386.
26. Oh J.K., Hatle L., Tajik A.J., Little W.C. Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. J Am Coll Cardiol 2006, 47:500-506.
27. Michele D.E., Gomez C.A., Hong K.E., Westfall M.V., Metzger J.M. Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hypertrophy-independent, and improved by beta-blockade. Circ Res 2002, 91:255-262.
28. Westfall M.V., Albayya F.P., Turner I.I., Metzger J.M. Chimera analysis of troponin I domains that influence Ca(2+)-activated myofilament tension in adult cardiac myocytes. Circ Res 2000, 86:470-477.
29. Yasuda S., Townsend D., Michele D.E., Favre E.G., Day S.M., Metzger J.M. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005, 436:1025-1029.
30. Yasuda S.I., Sugiura S., Kobayakawa N., Fujita H., Yamashita H., Katoh K., et al. A novel method to study contraction characteristics of a single cardiac myocyte using carbon fibers. Am J Physiol Heart Circ Physiol 2001, 281:H1442-H1446.
31. Coutu P., Bennett C.N., Favre E.G., Day S.M., Metzger J.M. Parvalbumin corrects slowed relaxation in adult cardiac myocytes expressing hypertrophic cardiomyopathy-linked alpha-tropomyosin mutations. Circ Res 2004, 94:1235-1241.
32. Coutu P., Metzger J.M. Genetic manipulation of calcium-handling proteins in cardiac myocytes. II. Mathematical modeling studies. Am J Physiol Heart Circ Physiol 2005, 288:H613-H631.
33. Metzger J.M., Michele D.E., Rust E.M., Borton A.R., Westfall M.V. Sarcomere thin filament regulatory isoforms. Evidence of a dominant effect of slow skeletal troponin I on cardiac contraction. J Biol Chem 2003, 278:13118-13123.
34. Westfall M.V., Borton A.R., Albayya F.P., Metzger J.M. Myofilament calcium sensitivity and cardiac disease: insights from troponin I isoforms and mutants. Circ Res 2002, 91:525-531.
35. Westfall M.V., Rust E.M., Metzger J.M. Slow skeletal troponin I gene transfer, expression, and myofilament incorporation enhances adult cardiac myocyte contractile function. Proc Natl Acad Sci U S A 1997, 94:5444-5449.
36. Bers D.M. Excitation-contraction coupling and cardiac contractile force 2001, Kluwer Academic Publishers, Dordrecht; Boston. 2nd ed.
37. Sen-Chowdhry S., Syrris P., McKenna W.J. Genetics of restrictive cardiomyopathy. Heart Fail Clin 2010, 6:179-186.
38. Palpant N.J., Day S.M., Herron T.J., Converso K.L., Metzger J.M. Single histidine-substituted cardiac troponin I confers protection from age-related systolic and diastolic dysfunction. Cardiovasc Res 2008, 80:209-218.
39. Tardiff J.C., Factor S.M., Tompkins B.D., Hewett T.E., Palmer B.M., Moore R.L., et al. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J Clin Invest 1998, 101:2800-2811.
40. Gordon A.M., Homsher E., Regnier M. Regulation of contraction in striated muscle. Physiol Rev 2000, 80:853-924.
41. Semsarian C., Ahmad I., Giewat M., Georgakopoulos D., Schmitt J.P., McConnell B.K., et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 2002, 109:1013-1020.
42. Tsoutsman T., Chung J., Doolan A., Nguyen L., Williams I.A., Tu E., et al. Molecular insights from a novel cardiac troponin I mouse model of familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 2006, 41:623-632.
43. Fatkin D., McConnell B.K., Mudd J.O., Semsarian C., Moskowitz I.G., Schoen F.J., et al. An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest 2000, 106:1351-1359.
44. Knollmann B.C., Potter J.D. Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. Trends Cardiovasc Med 2001, 11:206-212.
45. Fentzke R.C., Buck S.H., Patel J.R., Lin H., Wolska B.M., Stojanovic M.O., et al. Impaired cardiomyocyte relaxation and diastolic function in transgenic mice expressing slow skeletal troponin I in the heart. J Physiol 1999, 517(Pt 1):143-157.
46. Cho M.C., Rapacciuolo A., Koch W.J., Kobayashi Y., Jones L.R., Rockman H.A. Defective beta-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression. J Biol Chem 1999, 274:22251-22256.